Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Non-Crosslinked Hyaluronic Acid Redensity 1 ® Supports Cell Viability, Proliferation, and Collagen Deposition in Early Burn Management.

Liao Z., Chen X., Brusini R., Faivre J., Applegate LA., Flegeau K.

Laboratory Study on Chronic Wound, Burns, Scar, published in Pharmaceutics (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Pharmaceutics (2025)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
41599128
PMCID
PMC12845186
DOI
10.3390/pharmaceutics18010021
Citations
1

Abstract (original English)

Background: /Objectives: Burn injuries pose a significant challenge due to tissue damage and impaired healing. Cell-based therapies offer promise by delivering therapeu-tic cells to the wound site. However, effective cell delivery remains a critical hurdle. This study investigates the potential of non-cross-linked hyaluronic acid (HA) as a simple and versatile carrier for delivering autologous keratinocytes and fibroblasts to treat early burn wounds. Methods: Primary keratinocytes and fibroblasts were isolated from uninjured adult skin. In addition, fibroblasts and adipose stem cells (ASC) from polydactyly and progenitor fibroblasts were used. Non-cross-linked HA Redensity 1® (RD1) solutions of varying concentrations were prepared and applied on various in vitro models. Cell viabil-ity, proliferation, migration and collagen stimulation were assessed using standard as-says. Additionally, cells were suspended in Redensity 1 and applied a the in vitro de-epidemalized dermis (DED) wound model to examine cell delivery and tissue refor-mation. Results: Preliminary data demonstrated the feasibility of using non-cross-linked HA RD1 gel as a cell carrier. RD1 gel enhanced cell viability, retention, migration and col-lagen deposition. Histological analysis revealed improved cell adhesion and migration. Conclusions: This study provides valuable insight into the potential of non-cross-link

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research